CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 231 enrolled
Drug / intervention
Duloxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00408421
NCT00408421Phase 3Completed

Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain

Eli Lilly and Company·interventional·Posted Dec 7, 2006·Updated Aug 19, 2009

In Brief

A Phase 3 clinical trial evaluating Duloxetine and placebo for Osteoarthritis Knee Pain. Completed, enrolled 231 participants across 27 sites in 3 countries.

Detailed Summary

The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPuerto Rico, Romania, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 7, 2006
Enrollment StartNov 1, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.6 years ago

Interventions

Duloxetinedrug

placebodrug